Japan AI-Enabled Medical Devices Market (2026 - 2033)

Japan AI-enabled Medical Devices Market Summary

The Japan AI-enabled medical devices market size was valued at USD 68.8 million in 2025 and is projected to grow USD 85.0 million in 2026 to USD 393.0 million by 2033, at a CAGR of 24.4% from 2026 to 2033. Market growth is driven by the increasing integration of AI into medical imaging equipment, rising adoption of AI-assisted diagnostic software, and growing demand for efficient clinical workflows. The expanding use of AI in patient monitoring, cardiac diagnostics, endoscopy and neurological assessment further supports market development.

In addition, Japan's initiatives to accelerate the commercialization of Software as a Medical Device (SaMD), advances in medical imaging and data analytics, and the integration of AI into hospital information systems are strengthening the adoption of AI-enabled medical technologies across the healthcare sector.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Market Dynamic

Japan’s AI-enabled medical devices market is driven by rising chronic disease prevalence, growing demand for diagnostic efficiency, and government support for healthcare digitalization. Advancements in AI-based medical imaging, endoscopy, cardiology, and patient monitoring are expanding clinical applications. However, limited reimbursement, stringent regulatory requirements, cybersecurity concerns, and high implementation costs remain key restraints. Continued regulatory support, technological innovation, and strategic partnerships are expected to strengthen market adoption.

Market Concentration & Characteristics

The Japan AI-enabled medical devices market is highly innovative. Technological innovation is advancing through the integration of deep learning, automated image analysis, real-time AI assistance, and AI-enabled clinical decision support. For instance, in July 2026, Fujifilm Corporation developed AI-based software for detecting cerebral aneurysms from magnetic resonance angiography (MRA) images, which received Japan's first regulatory approval for a concurrent-read AI-enabled medical device. The software uses deep learning to identify suspected cerebral aneurysms with a maximum diameter of 2 mm or more and highlights the suspected lesions on MRA and 3D images.

Market consolidation through mergers and acquisitions (M&A) is strengthening capabilities in AI-enabled medical devices by expanding technology portfolios and integrating AI algorithms with wearable biosensors and remote patient monitoring solutions. For instance, in August 2026, iRhythm announced an agreement to acquire VitalConnect for approximately USD 287.5 million, expanding its capabilities in wearable biosensors, ambulatory cardiac monitoring, multi-vital monitoring, and AI-enabled algorithms, complementing its commercially available Zio ECG system in Japan.

To learn more about this report, Download Free Sample Report

Japan’s evolving regulatory framework, including PMDA review guidance for AI-enabled medical devices, post-approval change management under IDATEN, and dedicated initiatives for Software as a Medical Device (SaMD), is improving regulatory clarity and supporting product commercialization. These measures facilitate the evaluation, approval, and updating of AI-enabled technologies while maintaining safety and efficacy requirements. However, compliance with clinical validation, regulatory review, and reimbursement requirements continues to influence product development timelines and market entry.

AI medical-device companies are expanding into international markets to broaden their commercial reach and increase the adoption of AI-assisted diagnostic technologies. For instance, in April 2026, LPIXEL Inc. announced regulatory approvals for its EIRL medical imaging AI series in six ASEAN markets - Vietnam, the Philippines, Thailand, Indonesia, Malaysia, and Singapore. The approvals cover AI-assisted chest X-ray analysis, including suspected lung abnormality detection and tuberculosis probability classification, supporting the company’s regional commercialization strategy.

Analyst Perspective

Japan’s AI-enabled medical devices market is progressing from established applications in medical imaging and endoscopy toward broader adoption across neurological diagnostics, cardiovascular monitoring, and intraoperative surgical guidance. A structured regulatory framework, increasing product approvals, and dedicated SaMD initiatives support commercialization, while reimbursement pathways influence clinical adoption and market access. Opportunities are particularly relevant in cognitive assessment, real-time surgical assistance, and AI-enabled patient monitoring, where specialized technologies address evolving clinical needs. International expansion, strategic partnerships, and acquisitions are further strengthening technology portfolios and commercial reach.

By Application

The AI medical imaging segment held the largest market share of 70.6% in 2025. The segment growth is supported by the country’s high density of diagnostic imaging equipment and a growing number of PMDA-approved AI-based software medical devices. For instance, according to the study published by NCBI in June 2026, as of September 2025, Japan had 51 PMDA-approved AI-utilizing SaMD products, of which 24 were classified under medical imaging, making imaging the largest AI medical device application category in the country. These products span chest CT and X-ray, brain MRI, breast ultrasound, and musculoskeletal imaging, with applications including pulmonary nodule detection, quantification of interstitial lung disease, pneumonia identification, intracranial aneurysm detection, breast lesion characterization, and fracture detection.

The AI neurology & neurological diagnostics is expected to grow at the fastest CAGR during the forecast period. The increasing adoption of AI-based cognitive assessment technologies is expanding the application of artificial intelligence in neurological diagnostics, particularly for the early identification and assessment of cognitive decline and dementia. AI-enabled systems analyze patient-generated clinical information and support standardized cognitive-function assessment. For instance, FRONTEO Inc. and Shionogi & Co., Ltd. are jointly developing SDS-881, a conversational AI program medical device for cognitive-function testing. The system uses FRONTEO's proprietary KIBIT AI to analyze 10 minutes or more of free-flowing conversation between patients and healthcare professionals to determine the presence or absence of cognitive decline.

By Disease Area

The oncology diagnostics segment held the largest market share of 38.6% in 2025. The segment growth is supported by the country's high cancer burden and the growing use of AI across cancer detection, diagnosis, screening, and pathology. The oncology AI landscape has historically been concentrated in medical image analysis, particularly endoscopic and radiological applications. For instance, the 2025 Cancer Science review identified 18 AI-SaMD products approved in Japan for tumor-related applications as of May 2024, of which 9 (50%) supported endoscopic diagnosis. The review also highlighted active research in radiological image analysis, while research activity is expanding into omics analysis, natural-language processing, and large language models. This indicates that oncology is progressing from image-based AI to broader applications that involve clinical and molecular information.

To learn more about this report, Download Free Sample Report

The respiratory and pulmonary diseases segment is expected to grow at the fastest CAGR during the forecast period. The application of AI in respiratory healthcare is expanding across pulmonary imaging, lung cancer screening, and the assessment of respiratory abnormalities, with AI increasingly supporting the interpretation of complex chest imaging data. Lung cancer remains one of the major respiratory health burdens in Japan, while conditions such as chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), and other pulmonary disorders require repeated imaging, physiological measurements, and longitudinal assessment. For instance, a 2025 review from Osaka University highlighted the increasing use of AI in respiratory diagnosis, particularly for early detection of abnormalities and lung cancer using medical imaging.

Key Japan AI-enabled Medical Devices Company Insights

Key companies in Japan’s AI-enabled medical devices market are focusing on AI-assisted medical imaging, automated image interpretation, computer-aided detection and diagnosis, AI-enabled endoscopy, cardiovascular diagnostics, and patient monitoring to improve diagnostic accuracy and clinical workflow efficiency. Manufacturers are integrating deep-learning algorithms, image reconstruction technologies, real-time lesion detection, and clinical decision-support software into medical devices to support the early detection and assessment of diseases.

Key Japan AI-enabled Medical Devices Companies

• Cybernet Systems Corporation

• NEC Corporation

• Fujifilm Corporation

• LPIXEL Inc.

• AI Medical Service Inc.

• Canon Medical Systems Corporation

• Konica Minolta, Inc.

• DoctorNet Co., Ltd.

• Cardio Intelligence Inc.

• Aillis Inc.

• Fujitsu Limited

Recent Developments

• In May 2026, AI Medical Service received Japanese manufacturing and marketing approval for gastroAI model-G3, an AI-based endoscopic image diagnosis support software designed for gastric endoscopy. The product represents the company’s third-generation gastric endoscopy AI platform and supports endoscopic diagnosis.

• In March 2026, Cardio Intelligence launched the SmartRobin AI Series B, a long-term ECG analysis software that uses AI to automatically detect atrial fibrillation. The product supports ECG review for patients undergoing follow-up after AF treatment, patients with suspected AF, and patients receiving irregular-heartbeat alerts.

• In October 2025, Aillis began providing nodoca 3, an updated AI medical device incorporating a COVID-19 determination function. The system uses images of the pharynx together with patient information to support diagnosis of COVID-19, expanding the application of the nodoca platform beyond influenza.

Japan AI-Enabled Medical Devices Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of industry trends in each sub segment from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the Japan AI-enabled medical devices market on the basis of application and disease area:

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • AI Medical Imaging

    • Radiology AI

    • AI-Assisted Image Interpretation

    • Computer-Aided Detection/Diagnosis

    • Other Imaging AI

  • AI-Enabled Endoscopy

  • AI Cardiology & Cardiac Diagnostics

    • ECG Analysis

    • Arrhythmia Detection

    • Other AI-Enabled Cardiac Diagnostics

  • AI Neurology & Neurological Diagnostics

    • EEG Analysis

    • Neurological Monitoring

    • Other AI-Enabled Neurological Devices

  • AI Patient Monitoring & Physiological Monitoring

  • Other AI-Enabled Medical Devices

• Disease Area Outlook (Revenue, USD Million, 2021 - 2033)

  • Oncology

  • Cardiovascular Diseases

  • Neurological Disorders

  • Gastrointestinal Disorders

  • Respiratory and Pulmonary Diseases

  • Musculoskeletal and Orthopedic Conditions

  • Other Disease Areas

Research Methodology

The Japan AI-enabled medical devices market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each Japan AI-enabled medical devices segment quantified using the revenue-capture definitions in the table below.

Estimation Model

The Japan AI-enabled medical devices market was estimated using supply-side and demand-side models. Public data, product evidence, existing primary research, and internal databases were used to validate the key assumptions. The model covers 2021 to 2033. Values for 2021 to 2024 are modeled historical estimates, 2025 is the base year, and 2026 to 2033 are forecasts. All annual estimates were built from the underlying drivers rather than applying one common growth rate to every segment.

The methodology included:

Model 1: Commodity Flow Analysis

Commodity flow analysis is the supply-side methodology used to derive and cross-check the Japan AI-enabled medical devices market size. The approach reconstructs the market revenue pool from company-level financial information, government shipment statistics, and product-level revenue estimates.

To learn more about this report, Download Free Sample Report

Model 2: Demand Based Market Sizing Framework

The demand model starts with Japanese healthcare facilities and follows demand through equipment ownership or procedure performance, digital readiness, product availability, paying sites, AI licences, units, or tests per site, realized Japan price, and revenue.

• Step 1: Healthcare Facility Base - Identify relevant hospitals and clinics based on facility type, bed capacity, and availability of relevant clinical services.

• Step 2: Equipment Ownership and Procedure Base - Assess medical equipment availability and the volume of clinical procedures relevant to each AI-enabled medical device application.

• Step 3: Digital Readiness - Evaluate electronic health record adoption and the digital infrastructure required to support AI implementation.

• Step 4: Product Availability and Adoption - Assess regulatory approval, commercial availability, clinical adoption, and evidence of paid implementation.

• Step 5: Application-Specific Demand - Estimate demand using relevant drivers, including software licenses, equipment installations, diagnostic tests, and patient monitoring volumes.

• Step 6: Pricing and Revenue Estimation - Evaluate product pricing, subscription fees, service charges, reimbursement mechanisms, and the attributable value of AI technology.

• Step 7: Segment and Care-Setting Allocation - Allocate estimated demand across AI application segments and healthcare settings, ensuring consistent classification and avoiding double counting.

• Step 8: Model Validation and Reconciliation - Validate estimates against government statistics, manufacturer disclosures, equipment shipment data, and consistency checks across market segments.

Overall approach: The framework combines healthcare infrastructure, digital readiness, AI adoption, application-specific demand, and pricing evidence to estimate the market systematically. Each application follows its relevant demand drivers, with validation checks ensuring consistency across segments and healthcare settings.

Delivered Customizations

This report has been delivered with the following In-depth customizations